Challenges in the diagnosis and treatment of pulmonary arterial hypertension.

2.50
Hdl Handle:
http://hdl.handle.net/10147/255061
Title:
Challenges in the diagnosis and treatment of pulmonary arterial hypertension.
Authors:
Vachiéry, Jean-Luc; Gaine, Sean
Affiliation:
Pulmonary Vascular Diseases and Heart Failure Clinic, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. # National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Citation:
Challenges in the diagnosis and treatment of pulmonary arterial hypertension. 2012, 21 (126):313-20 Eur Respir Rev
Journal:
European respiratory review : an official journal of the European Respiratory Society
Issue Date:
1-Dec-2012
URI:
http://hdl.handle.net/10147/255061; http://err.ersjournals.com/cgi/content/full/21/126/313?ijkey=IfBwQvmSo9332&keytype=ref&siteid=ersjnls
DOI:
10.1183/09059180.00005412
PubMed ID:
23204119
Abstract:
Advances in the diagnosis and management of pulmonary arterial hypertension (PAH) have resulted in significant improvements in outcomes for patients with this devastating and progressive disease. However, because of the non-specific nature of its symptoms, and the low level of suspicion among clinicians, prompt and accurate diagnosis of PAH as a rare disease remains a challenge. This article explains some of the issues that need to be addressed when faced with a patient with suspected PAH and describes how noninvasive and invasive techniques can be used effectively to ensure an accurate diagnosis. The availability of PAH-specific therapy means that once diagnosed, patients have a much greater chance of survival than they would have had in the past. However, despite improved survival, mortality is still high and, therefore, there is still room for improvement. It is currently recommended that patients with an inadequate clinical response to treatment receive sequential combination therapy; however, supportive data are still scarce. Although there is no clear explanation, these findings may be explained by the design and end-points chosen in clinical trials, the changing population of PAH and a need to improve the management strategy in this disease. Indeed, there is a clear need for randomised controlled studies that investigate whether adopting individualised treatment strategies, including upfront combination therapy, could help to optimise long-term management of patients with PAH.
Item Type:
Article
Language:
en
ISSN:
1600-0617

Full metadata record

DC FieldValue Language
dc.contributor.authorVachiéry, Jean-Lucen_GB
dc.contributor.authorGaine, Seanen_GB
dc.date.accessioned2012-12-10T11:29:24Z-
dc.date.available2012-12-10T11:29:24Z-
dc.date.issued2012-12-01-
dc.identifier.citationChallenges in the diagnosis and treatment of pulmonary arterial hypertension. 2012, 21 (126):313-20 Eur Respir Reven_GB
dc.identifier.issn1600-0617-
dc.identifier.pmid23204119-
dc.identifier.doi10.1183/09059180.00005412-
dc.identifier.urihttp://hdl.handle.net/10147/255061-
dc.identifier.urihttp://err.ersjournals.com/cgi/content/full/21/126/313?ijkey=IfBwQvmSo9332&keytype=ref&siteid=ersjnls-
dc.description.abstractAdvances in the diagnosis and management of pulmonary arterial hypertension (PAH) have resulted in significant improvements in outcomes for patients with this devastating and progressive disease. However, because of the non-specific nature of its symptoms, and the low level of suspicion among clinicians, prompt and accurate diagnosis of PAH as a rare disease remains a challenge. This article explains some of the issues that need to be addressed when faced with a patient with suspected PAH and describes how noninvasive and invasive techniques can be used effectively to ensure an accurate diagnosis. The availability of PAH-specific therapy means that once diagnosed, patients have a much greater chance of survival than they would have had in the past. However, despite improved survival, mortality is still high and, therefore, there is still room for improvement. It is currently recommended that patients with an inadequate clinical response to treatment receive sequential combination therapy; however, supportive data are still scarce. Although there is no clear explanation, these findings may be explained by the design and end-points chosen in clinical trials, the changing population of PAH and a need to improve the management strategy in this disease. Indeed, there is a clear need for randomised controlled studies that investigate whether adopting individualised treatment strategies, including upfront combination therapy, could help to optimise long-term management of patients with PAH.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to European respiratory review : an official journal of the European Respiratory Societyen_GB
dc.titleChallenges in the diagnosis and treatment of pulmonary arterial hypertension.en_GB
dc.typeArticleen
dc.contributor.departmentPulmonary Vascular Diseases and Heart Failure Clinic, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. # National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.en_GB
dc.identifier.journalEuropean respiratory review : an official journal of the European Respiratory Societyen_GB
dc.description.linkToll link provided with permission of the European Respiratory Society. Eur Respir Rev December 2012 21:313-320; doi:10.1183/09059180.00005412”-
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.